Hexagon Nutrition IPO vs Bagmane Prime Office REIT: Detailed Review, GMP, Financials & Investment Ve

IPO Analysis
Hexagon Nutrition IPO vs Bagmane Prime Office REIT: Detailed Review, GMP, Financials & Investment Ve
IPO Analysis27 May 2026by IPOup Team1 views

Hexagon Nutrition IPO vs Bagmane Prime Office REIT: Detailed Review, GMP, Financials & Investment Ve

A detailed yet practical breakdown of Hexagon Nutrition IPO and Bagmane Prime Office REIT covering GMP trends, financials, risks, subscription data, and who these investments actually suit.


Most IPOs try very hard to look exciting.

Big promises. Huge growth projections. Influencers calling everything the “next multibagger” before the company even lists.

Hexagon Nutrition and Bagmane Prime Office REIT feel different.

Not because they’re small. Not because they’re conservative. Mostly because both actually seem grounded in real businesses instead of market hype.

One company sells nutrition products and micronutrient solutions across global markets. The other owns premium office parks in Bengaluru rented out to companies like Google and Amazon.

Completely different sectors. Completely different investment logic.

But both have quietly become some of the more discussed public market opportunities of 2026.

So instead of treating this like another “apply or avoid” article, let’s look at what actually matters.

Hexagon Nutrition IPO: Not Flashy, But Surprisingly Solid

Hexagon Nutrition has been around since 1993, which already makes it older than many companies entering the market these days.

The business operates in nutritional products, micronutrient premixes, clinical nutrition, and therapeutic food solutions. Most retail investors probably haven’t heard of the company directly, but the products themselves are more common than people realize.

The company supplies nutritional blends used in fortified foods and healthcare products. It also owns brands like Pentasure, Pediagold, and Obesigo, which are relatively known in hospital nutrition and dietary supplement spaces.

One thing that immediately stands out is the export exposure.

More than 60% of revenue reportedly comes from international markets.

That gives Hexagon access to larger demand opportunities outside India, but it also creates forex-related risk that investors shouldn’t ignore.

Hexagon Nutrition IPO Details

Particulars

Details

IPO Dates

June 5 – June 9, 2026

Price Band

₹42 – ₹45

Lot Size

333 Shares

Minimum Investment

Around ₹14,985

Issue Size

₹138.87 Crore

Exchange

NSE & BSE

IPO Type

100% OFS

The OFS structure is important here.

This is not a fresh issue where the company raises money for expansion or debt repayment. Existing shareholders are selling stake through the IPO.

That doesn’t automatically make the issue unattractive, but it changes the conversation slightly. Investors are essentially evaluating the current business quality rather than future expansion funded through IPO proceeds.

The Financials Look Better Than Most Expected

A lot of smaller IPOs usually struggle with profitability consistency.

Hexagon’s recent numbers actually look fairly decent.

Profit after tax reportedly doubled year-on-year, which is meaningful for a business operating in a relatively stable industry.

Even more interesting, the FY26 nine-month PAT has already crossed the full FY25 profit figure.

That generally suggests improving operational efficiency and margin expansion.

Financial Metric

Value

FY25 PAT

₹24.38 Crore

FY26 9M PAT

₹27 Crore

Debt-to-Equity

0.18

Export Revenue

60%+

The debt levels also appear manageable, which matters much more in the current market environment than many investors realize.

What About GMP?

At the moment, the GMP trend appears muted.

And honestly, that makes sense.

Hexagon doesn’t look like the kind of IPO built for explosive listing-day gains. The market seems to be treating it more like a long-term healthcare and nutrition story rather than a short-term trading opportunity.

That may disappoint aggressive traders.

But for patient investors, the business itself is probably more important than the grey market noise.

India’s nutrition and food fortification market still has significant long-term potential, especially with rising health awareness and government-backed nutrition initiatives.

Bagmane Prime Office REIT: A Completely Different Investment Story

Bagmane Prime Office REIT isn’t really competing with Hexagon directly.

A REIT works very differently from a normal equity IPO.

You’re not betting primarily on product growth or aggressive earnings expansion. Instead, you’re investing in income-generating real estate assets that distribute rental income over time.

Bagmane’s portfolio consists of premium office properties in Bengaluru — one of India’s strongest commercial office markets.

And the tenant profile is probably the biggest reason institutional investors showed strong interest.

The portfolio includes companies like:

  • Google

  • Amazon

  • Nvidia

These aren’t short-term tenants signing temporary leases. They represent long-duration commercial demand tied to India’s growing technology ecosystem.

Bagmane Prime Office REIT Details

Particulars

Details

Listing Date

May 15, 2026

Price Band

₹95 – ₹100

Lot Size

150 Units

Minimum Investment

Around ₹15,000

Issue Size

₹3,405 Crore

Fresh Issue

₹2,390 Crore

OFS Component

₹1,015 Crore

Unlike Hexagon, Bagmane includes a large fresh issue component, which means capital flows back into the trust structure for future growth and acquisitions.

Occupancy Levels Are Extremely Strong

One number that immediately grabs attention is the occupancy rate.

Reported occupancy stood close to 98.8%, which is extremely high for commercial office real estate.

That matters because REIT performance depends heavily on stable rental cash flow.

The stronger the occupancy, the more predictable the income generation becomes.

Financial performance has also remained relatively stable.

Financial Metric

Value

FY25 Revenue

₹2,391 Crore

FY25 Net Profit

₹897 Crore

FY26 9M Profit

₹829 Crore

Occupancy Rate

98.8%

But There’s One Risk Investors Shouldn’t Ignore

Almost the entire Bagmane portfolio is concentrated in Bengaluru.

That’s both a strength and a weakness.

If Bengaluru continues dominating India’s GCC and technology office demand, the REIT benefits massively.

But if office leasing demand weakens or technology companies reduce expansion, the concentration risk becomes meaningful.

There’s also the interest-rate angle.

Neither opportunity looks built around unrealistic hype.

And after some of the IPOs the market has seen recently, that’s probably a good thing.

Comments

No comments yet

Be the first to share your thoughts!